HER2- breast cancer
Oncology · 2023–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| olaparib Adjuvant treatment of HER2-negative high-risk early breast cancer with confirmed germline BRCA1 or BRCA2 mutation in patients who have previously been treated… | Nov 2023 | Recommended with restriction | 14 individuals Medical Oncology Group · Breast Cancer Network Australia |
Who spoke
Medical Oncology Group · Breast Cancer Network Australia
What the PBS pays
$61M in government benefit over 2024–25, across 9,438 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| olaparib | $60.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| olaparibOlaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | recommended restricted | 2023-05 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.